Search Results - "LINSE, R"

Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis by Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., Stadler, R., Weichenthal, M., Eigentler, T.K., Ellwanger, U., Hauschild, A.

“…More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent disease within the first 3 years after surgery. The aim of…”
Get full text

Adjuvant low-dose interferon alpha 2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis by Garbe, C, Radny, P, Linse, R, Dummer, R, Gutzmer, R, Ulrich, J, Stadler, R, Weichenthal, M, Eigentler, T K, Ellwanger, U, Hauschild, A

“…BACKGROUND: More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent disease within the first 3 years after surgery…”
Get full text

Topical tacrolimus in granuloma annulare and necrobiosis lipoidica by Harth, W., Linse, R.

Get full text

Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study by Schadendorf, D, Hauschild, A, Ugurel, S, Thoelke, A, Egberts, F, Kreissig, M, Linse, R, Trefzer, U, Vogt, T, Tilgen, W, Mohr, P, Garbe, C

“…Background: Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours. The purpose of this…”
Get full text

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma : a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DECOG) by HAUSCHILD, A, GARBE, C, ACHTELIK, W, MOHR, P, KAUFMANN, R, FEY, M, ULRICH, J, TILGEN, W, STOLZ, W, ELLWANGER, U, SEITER, S, DUMMER, R, UGUREL, S, SEBASTIAN, G, NASHAN, D, LINSE, R

“…In several phase II-trials encouraging tumour responses rates in advanced metastatic melanoma (stage IV; AJCC-classification) have been reported for the…”
Get full text

Using mycobacterium cell wall fraction to decrease equine chorionic gonadotropin after abortion by Fedorka, Carleigh E., Schnobrich, Maria R., Muderspach, Natacha D., Scoggin, Kirsten E., Dedman, Madison T., Weigle, Kelly E., May, Mary G., Twist, Heidi, Linse, Cara R., Douglas, Robert H., Troedsson, Mats H. T.

“…Background Equine embryonic loss following the development of endometrial cups delays return to cyclicity due to the production of equine chorionic…”
Get full text

The borderline syndrome in psychosomatic dermatology Overview and case report by Harth, W, Mayer, K, Linse, R

“…ABSTRACT The borderline syndrome is one of the most severe disturbances of psychosomatic dermatology. Patients with borderline syndrome are situated ‘on the…”
Get full text

Botulinophilia: contraindication for therapy with botulinum toxin by Harth, W, Linse, R

“…Botulinum toxin inhibits neuromuscular transmission and is one of the most potent toxins. It has proven to be effective in the treatment of hyperhidrosis and…”
Get more information

Dermatological symptoms and sexual abuse: a review and case reports by Harth, W, Linse, R

“…ABSTRACT Dermatological symptoms in cases of sexual abuse can be very diverse. To establish a causal relationship between skin diseases and sexual abuse is…”
Get full text

Body dysmorphic disorder and life-style drugs. Overview and case report with finasteride by Harth, W, Linse, R

“…The body dysmorphic disorder is the repeated preoccupation with a minimal or non-evident defect and includes a wide spectrum of imagined defects in appearance…”
Get more information

Interpreting and using student ratings data: Guidance for faculty serving as administrators and on evaluation committees by Linse, Angela R.

“…This article is about the accurate interpretation of student ratings data and the appropriate use of that data to evaluate faculty. Its aim is to make…”
Get full text

Botulinophilia: contraindication for therapy with botulinum toxin by Harth, W., Linse, R.

Get full text

The sweat of patients with atopic dermatitis contains specific IgE antibodies to inhalant allergens by JUNG, K, SCHLENVOIGT, G, LADWIG, K, HERRMANN, D, MOTHS, C, LINSE, R, NEUMANN, C

“…We have investigated levels of total and specific IgE against inhalant allergens in the sweat of 15 patients with atopic dermatitis, 10 patients with allergic…”
Get full text

Autosomal recessive cutis laxa syndrome. A case report by Jung, K, Ueberham, U, Hausser, I, Bosler, K, John, B, Linse, R

“…Congenital cutis laxa (CCL) is a rare, genetically heterogeneous connective tissue disorder, manifested by loose, hanging skin, giving the appearance of…”
Get more information

The question of surgical therapy for necrolytic migratory erythema, a cutaneous disease by Siegel, R, Linse, R, Rau, B

“…Necrolytic migratory erythema (NME) is a rare paraneoplastic dermatologic condition. Its underlying cause is usually a pancreatic islet cell tumour with marked…”
Get full text

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group by KAUFMANN, Roland, SPIETH, Konstanze, SEBASTIAN, Günther, KRENGEL, Sven, KRETSCHMER, Lutz, GARBE, Claus, DUMMER, Reinhard, LEITER, Ulrike, MAUCH, Cornelia, VON DEN DRIESCH, Peter, VOGT, Thomas, LINSE, Ruthild, TILGEN, Wolfgang, SCHADENDORF, Dirk, BECKER, Jürgen C

“…Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma. As the…”
Get full text

Health-related Quality of Life Before and During Adjuvant Interferon-α Treatment for Patients With Malignant Melanoma (DeCOG-Trial) by ZIEFLE, Susanne, EGBERTS, Friederike, EIGENTLER, Thomas, BROCKMEYER, Norbert H, HEINZ, Andreas, HAUSCHILD, Axel, SCHAEFER, Martin, HEINZE, Sarah, VOLKENANDT, Matthias, SCHMID-WENDTNER, Monika, TILGEN, Wolfgang, LINSE, Ruthild, BOETTJER, Jörg, VOGT, Thomas, SPIETH, Konstanze

“…Adjuvant treatment with interferon-α (IFN-α) for patients with malignant melanoma can improve relapse-free and overall survival, but IFN-associated side…”
Get full text

Safety data on adjuvant treatment of cutaneous melanoma patients with interferon-alpha2b and pegylated interferon-alpha2b: An interim analysis of 285 patients treated in Germany by Eigentler, T. K., Gutzmer, R., Hauschild, A., Vogt, T., Linse, R., Garbe, C.

“…Abstract only 8561 Background: A multicenter, prospective randomized, phase III trial (EADO 2002/CMII) evaluating efficacy of interferon-a2b (IFNa) and of…”
Get full text

Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial by Hauschild, A., Volkenandt, M., Tilgen, W., Linse, R., Böttjer, J., Vogt, T., Spieth, K., Eigentler, T., Brockmeyer, N. H., Weichenthal, M.

“…Abstract only…”
Get full text

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis by Garbe, C, Radny, P, Linse, R, Dummer, R, Gutzmer, R, Ulrich, J, Stadler, R, Weichenthal, M, Eigentler, Tk, Ellwanger, U, Hauschild, A

“…More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent disease within the first 3 years after surgery. The aim of…”
Get full text